Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.70
Quick Ratio3.70
Price-To-Earnings
Trailing P/E Ratio-1.26
Forward P/E Ratio-2.92
P/E GrowthN/A
Sales & Book Value
Annual Sales$500,000.00
Price / Sales114.37
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book1.95
Profitability
EPS (Most Recent Fiscal Year)($2.39)
Net Income$-20,400,000.00
Net Margins-3,897.86%
Return on Equity-112.83%
Return on Assets-47.72%
Miscellaneous
Employees21
Outstanding Shares17,650,000
Celsion (NASDAQ:CLSN) Frequently Asked Questions
What is Celsion's stock symbol?
Celsion trades on the NASDAQ under the ticker symbol "CLSN."
When did Celsion's stock split? How did Celsion's stock split work?
Celsion's stock reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.
How were Celsion's earnings last quarter?
Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings data on Friday, May, 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.05. The biotechnology company earned $0.13 million during the quarter, compared to analysts' expectations of $0.13 million. Celsion had a negative return on equity of 112.83% and a negative net margin of 3,897.86%. View Celsion's Earnings History.
When is Celsion's next earnings date?
What price target have analysts set for CLSN?
2 brokers have issued 12 month price targets for Celsion's shares. Their predictions range from $7.00 to $9.00. On average, they anticipate Celsion's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Celsion.
Who are some of Celsion's key competitors?
Some companies that are related to Celsion include Menlo Therapeutics (MNLO), Spring Bank Pharma (SBPH), Tocagen (TOCA), Calithera Biosciences (CALA), XOMA (XOMA), Aldeyra Therapeutics (ALDX), SUMMIT THERAPEU/S (SMMT), Nature's Sunshine Products Common Stock (NATR), ContraFect (CFRX), Spero Therapeutics (SPRO), Iterum Therapeutics (ITRM), BioDelivery Sciences International (BDSI), RedHill Biopharma (RDHL), Sol Gel Technologies (SLGL) and Nabriva Therapeutics (NBRV).
Who are Celsion's key executives?
Celsion's management team includes the folowing people:
- Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 67)
- Mr. Jeffrey W. Church, CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec. (Age 61)
- Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 58)
- Dr. Nicholas Borys, Sr. VP & Chief Medical Officer (Age 59)
- Mr. Timothy J. Tumminello CPA, Chief Accounting Officer and Controller (Age 60)
Has Celsion been receiving favorable news coverage?
News headlines about CLSN stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celsion earned a coverage optimism score of 0.09 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.07 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Celsion's major shareholders?
Celsion's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sabby Management LLC (2.08%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion.
Which institutional investors are buying Celsion stock?
CLSN stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Insider Buying and Selling for Celsion.
How do I buy shares of Celsion?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celsion's stock price today?
One share of CLSN stock can currently be purchased for approximately $3.29.
How big of a company is Celsion?
Celsion has a market capitalization of $46.78 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-20,400,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Celsion employs 21 workers across the globe.
How can I contact Celsion?
Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]
MarketBeat Community Rating for Celsion (CLSN)
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
